看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' C2 P- D4 c I% {( x
' c. P' o) f( r; N% e/ b
% ?5 Y8 S+ r3 ?* d& g! t8 X
Currently available feasibility data for possible combination strategies. & G* G, S G% v' M$ y* l
————————————————————————————————" {0 V: ?; H7 }+ W8 x8 ~
Combination Feasibility according to preliminary data
1 Z6 D9 y$ @6 R+ ]' s. `0 l——————————————————————————————————
/ e8 U; W& i6 w- V- H" q1 HBevacizumab + sorafenib Yes, reduced dose
1 r! Q+ d) Z3 ` d1 K. K+ bBevacizumab + sunitinib† No
$ D, L2 n* [0 U+ MBevacizumab + temsirolimus Yes
5 L/ f; X$ V: I0 t9 _5 {Bevacizumab + everolimus Yes
- [2 M2 B/ W, Q P7 LSorafenib + sunitinib ?
0 F3 x8 _& c8 f# @, M- qSorafenib + temsirolimus Yes, reduced dose
. J0 k9 O' y7 C" q6 qSorafenib + everolimus Yes, reduced dose ) ~5 `# U! C) ~' ~* _7 m" j4 v
Sunitinib + temsirolimus† No
8 l6 g7 C4 e! xSunitinib + everolimus ? : G6 [4 B: P4 j8 w2 ]) ]
Temsirolimus + everolimus ? 1 O5 |, o5 _/ ~7 T) w* b4 x c
————————————————————
% E5 @8 R5 h! N) X! y7 R†Led to US FDA warning.
# h/ E( w/ ?4 o" b9 B I! r?: As yet unattempted combination.$ ]# ?8 x: Y9 \
|